641 related articles for article (PubMed ID: 22041254)
1. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
Robinson A; Kardos M; Kimball AB
J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
[TBL] [Abstract][Full Text] [Related]
2. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
Nast A; Schmitt J
J Am Acad Dermatol; 2013 Jun; 68(6):1040-1. PubMed ID: 23680196
[No Abstract] [Full Text] [Related]
3. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
Mattei PL; Corey KC; Kimball AB
J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
[TBL] [Abstract][Full Text] [Related]
4. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
6. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Bożek A; Reich A
Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
[TBL] [Abstract][Full Text] [Related]
8. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
Puzenat E; Bronsard V; Prey S; Gourraud PA; Aractingi S; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Paul C; Richard-Lallemand MA; Ortonne JP; Aubin F
J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():10-6. PubMed ID: 20443995
[TBL] [Abstract][Full Text] [Related]
9. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.
Berth-Jones J; Thompson J; Papp K;
Br J Dermatol; 2008 Aug; 159(2):407-12. PubMed ID: 18565187
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
[TBL] [Abstract][Full Text] [Related]
11. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
[TBL] [Abstract][Full Text] [Related]
13. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
14. Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis.
Gulliver W; Lynde C; Dutz JP; Vender RB; Yeung J; Bourcier M; Dion PL; Hong CH; Searles G; Poulin Y
J Cutan Med Surg; 2015; 19(1):22-7. PubMed ID: 25775659
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
17. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.
Berth-Jones J; Grotzinger K; Rainville C; Pham B; Huang J; Daly S; Herdman M; Firth P; Hotchkiss K
Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
[TBL] [Abstract][Full Text] [Related]
19. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.
Puig L; López A; Vilarrasa E; García I
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1633-53. PubMed ID: 24033851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
